Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Frontiers Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials - ScienceDirect
Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology
Rucaparib Bests Physician's Choice for BRCA+ mCRPC
The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials - ScienceDirect
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer in the TRITON3 Trial – Oliver Sartor
PDF] Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (
Current Oncology, Free Full-Text
Advanced Prostate Cancer: Treatment Advances and Future Directions: Trends in Cancer
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
Rucaparib or physician's choice in metastatic prostate cancer -ORCA
de
por adulto (o preço varia de acordo com o tamanho do grupo)
